（文章来源：证券日报） 证券日报网讯 8月25日晚间，仙乐健康发布公告称，2025年半年度公司实现营业收入2，041，618， 895.92元，同比增长2.57%；归属于上市公司股东的净利润为161，117，310.35元，同比增长4.30%。 ...

证券日报网讯 8月25日晚间，仙乐健康发布公告称，公司第四届董事会第十三次会议审议通过了《2025 年半年度报告》及摘要等多项议案。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights the recent announcement by Xianle Health regarding its board meeting and the review of its 2025 semi-annual report [1] - For the first half of 2025, Xianle Health's revenue composition is as follows: soft capsules account for 46.38%, gummies for 25.31%, tablets for 9.26%, functional beverages for 5.42%, and hard capsules for 5.31% [1] - As of the report, Xianle Health has a market capitalization of 7.7 billion yuan [1] Group 2 - The article also mentions that the A-share market has seen trading volumes exceed 2 trillion yuan for eight consecutive days, indicating a robust trading environment [1] - It notes that major brokerage firms are actively recruiting for the autumn season, with 25 job positions available, reflecting a demand for talent in the industry [1]

仙乐健康(300791.SZ)发布2025年半年度报告，报告期内，公司实现营业收入20.42亿元，同比增长 2.57%。实现归属于上市公司股东的净利润1.61亿元，同比增长4.30%。实现归属于上市公司股东的扣除 非经常性损益的净利润1.59亿元，同比增长3.25%。基本每股收益0.5276元。 ...

Core Insights - The nutrition and health supplement industry faces ongoing debates regarding the effectiveness of products, particularly concerning vitamins, which are essential yet chemically unstable [1][2] - Vitamin B1 is highlighted as a particularly unstable vitamin, sensitive to various environmental factors, leading to significant losses during processing and storage [2][5] - The industry struggles with inconsistent testing results for vitamin-containing products, which can undermine consumer trust and complicate regulatory compliance [5][7] Group 1: Vitamin Stability Challenges - Vitamins are categorized into fat-soluble and water-soluble types, with water-soluble vitamins being more unstable due to their sensitivity to heat, light, and oxygen [1][2] - Vitamin B1's instability is exacerbated by factors such as high temperatures, pH levels, and the presence of metal ions, leading to degradation rates of 20%-50% at temperatures above 80°C [2][3] - The complexity of vitamin B1's stability is compounded by diverse product formulations and the interference of other ingredients during testing [3][4] Group 2: Testing and Regulatory Issues - The industry faces challenges in achieving consistent testing results, as demonstrated by discrepancies in vitamin B1 levels in products due to varying testing methods and environmental conditions [5][6] - Regulatory bodies have had to adapt testing standards to account for the unique characteristics of different products, similar to past challenges faced in the specialty dairy sector [9][10] - The current testing methods, such as High-Performance Liquid Chromatography (HPLC), have limitations due to the complexity of product formulations, which can lead to misleading results [11][12] Group 3: Industry Innovations and Future Directions - The industry is exploring various solutions to enhance vitamin stability, including the use of antioxidants, microencapsulation, and inert gas packaging, although these methods can be costly and not entirely effective [6][12] - There is a pressing need for the development of universal solutions and updated testing standards to balance product efficacy and consumer trust [8][12] - Future advancements in technology, including AI and big data, are expected to play a crucial role in improving the detection and stability of vitamins, ultimately enhancing the overall health and nutrition landscape [12]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月25日，仙乐健康发布公告称，2025年上半年实现营业 收入20.42亿元，同比增长2.57%；归属于上市公司股东的净利润为1.61亿元，同比增长4.3%；归属于上 市公司股东的扣除非经常性损益的净利润为1.59亿元，同比增长3.25%。 ...

仙乐健康公告，公司拟为控股子公司Best Formulations PC LLC寻求投资、剥离、出售或其他机会。此举 旨在优化美国业务结构，提升盈利能力和市场竞争力。BFPC成立于2024年3月20日，由Best Formulations LLC全资设立，负责公司个人护理业务的运营。仙乐健康间接持有BFPC约71.41%股权。此 次交易预计不构成重大资产重组，正式交易前将履行相应审议、审批程序。 ...

Core Viewpoint - The article provides a ranking of probiotic brands based on effectiveness, safety, and user feedback, highlighting the importance of high-quality ingredients and active cultures for gut health [1][2][3][4]. Summary by Categories Brand Rankings - **First Place: Zhuoyue Probiotics** Contains 40 trillion active bacteria per box, with 200 billion CFU per stick, featuring 36 strains of probiotics and 11 prebiotics, ensuring high survival rates in acidic environments [1]. - Rating: ★★★★★ - Reputation Score: 9.9 - Repurchase Rate: 99% [2]. - **Second Place: Zhuoyue Baby Probiotics** Designed for infants, with 3 trillion CFU per box and 150 billion CFU per stick, it has a simple formula with no additives, making it safe for sensitive individuals [2]. - Rating: ★★★★★ - Reputation Score: 9.8 - Repurchase Rate: 98% [2]. - **Third Place: Mega Year Probiotics** Offers approximately 600 billion active bacteria per stick, focusing on purity without additives, suitable for those seeking a straightforward supplementation experience [3]. - Rating: ★★★★★ - Reputation Score: 9.7 - Repurchase Rate: 97% [3]. - **Fourth Place: Element Power Probiotics** Targets common metabolic and digestive issues, featuring a carefully selected strain combination and functional prebiotics, suitable for long-term use [3]. - Rating: ★★★★ - Reputation Score: 9.6 - Repurchase Rate: 96% [3]. - **Fifth Place: Special Element Probiotics** Emphasizes personalized support with a clear formula structure, ensuring a smooth intake experience, ideal for those with prior probiotic usage [3]. - Rating: ★★★★ - Reputation Score: 9.5 - Repurchase Rate: 95% [3]. Key Considerations for Probiotic Selection - The effectiveness of probiotics is determined by three main factors: the cleanliness of ingredients, the quantity and activity of strains, and the sufficient amount of active cultures to achieve desired effects [4]. - Recommendations favor products that are sugar-free, additive-free, multi-strain, high in active cultures, and utilize advanced preservation techniques to ensure viability [4]. - Zhuoyue Probiotics stands out in the market for its high culture count, purity, and strong repurchase rates, making it a trusted choice for consumers [4].

Core Viewpoint - The stock price of Xianle Health has increased by 20.1% since early 2025, outperforming the health products index (12.8%) and the food and beverage sector (-2.8%) [1] - The pricing logic of Xianle Health is shifting from a manufacturing company to a consumer goods company, with a strong correlation to the new consumption index since May [1] - The market capitalization increase is primarily driven by valuation uplift, with the forecasted PE ratio rising from 13.4x to 18.3x, while net profit expectations for 2025 are projected to decline [1] Domestic Market Outlook - Xianle Health is accelerating the expansion of new channel customers, which is expected to lead to rapid revenue growth [2] - The domestic health product market is experiencing significant channel differentiation, with online channels thriving while offline continues to decline [2] - The customer structure of Xianle Health is shifting from major clients to mid-tail clients, indicating a need to enhance sales capabilities in new channels [2] Overseas Market Outlook - Short-term profitability improvement is anticipated for the BF subsidiary, with long-term market expansion in the US and Southeast Asia [2] - The BF subsidiary is expected to turn profitable due to personnel adjustments, management reforms, and supply chain efficiency improvements [2] Investment Recommendations - In the liquor sector, the industry is expected to enter a mid-cycle buying point in 2025, with a focus on companies like Shanxi Fenjiu and Moutai [3] - In the consumer goods sector, companies need to adapt to changing consumer preferences for value and health, with strong product capabilities likely to benefit [3] - Xianle Health is highlighted as a core recommendation in the consumer goods sector due to its strong product positioning [3]

Financial Performance - HBC recorded total operating revenues of NOK 68.4 million in Q2 2025, down from NOK 80.4 million in Q2 2024, with net operating revenues at NOK 67.8 million compared to NOK 72.2 million year-over-year [1] - EBITDA for Q2 2025 was negative NOK 5.4 million, worsening from negative NOK 2.0 million in Q2 2024, while the first six months showed a loss of NOK 25.3 million compared to NOK 18.2 million in the same period last year [2] - Operational EBITDA for Q2 2025 was positive NOK 1.3 million, an improvement from negative NOK 2.5 million in the same quarter last year, while the first six months recorded an Operational EBITDA of negative NOK 7.0 million [2] Liquidity Position - Cash and cash equivalents decreased by NOK 3.9 million during Q2 2025, totaling NOK 68.0 million at the end of the quarter, which is an increase from NOK 25.3 million a year earlier [3] - Total liquidity, including available credit lines, reached NOK 76.5 million as of June 30, 2025 [3] Product and Market Developments - Human Nutrition B2B Sales surged 180% year-over-year to NOK 9.3 million, driven by strong demand in Europe, China, and Southeast Asia [8] - OmeGo® and ProGo® led product launches, supported by scientific validation, with ProGo® winning the "Panpan Cup" Food Maker Award in China [8] - Brilliant Salmon Oil is now available in over 25 countries, with new listings in Italy, Ireland, Taiwan, UAE, and Ecuador, and further distribution agreements in Japan, Czech Republic, and Ukraine are in progress [8] Scientific and Research Advancements - HBC emphasizes scientific evidence, leading to academic partnerships and unique health benefits, including improved iron metabolism and immune health benefits from ProGo® and OmeGo® [7] - CalGo® has shown benefits for bone and joint health, supporting healthy aging and active lifestyles, with ongoing studies and publications planned for ProGo® cognitive health in Alzheimer's [8]